BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock Has Average Target Price of $104.75 According to Analysts

Posted by Brenda Bartman on Oct 23rd, 2026

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the twenty-four brokerages that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, twenty have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $104.40.

Several analysts recently commented on the company. Citigroup dropped their price target on BridgeBio Pharma from $94.00 to $91.00 and set a “neutral” rating for the company in a research report on Monday. Mizuho increased their target price on shares of BridgeBio Pharma from $96.00 to $110.00 and gave the stock an “outperform” rating in a report on Tuesday, September 1st. Truist Financial upped their price objective on shares of BridgeBio Pharma from $102.00 to $107.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Bank of America boosted their price target on shares of BridgeBio Pharma from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of BridgeBio Pharma in a research note on Monday, October 5th.

Read Our Latest Stock Report on BBIO

BridgeBio Pharma Trading Up 0.6%

Shares of NASDAQ BBIO opened at $68.12 on Friday. The business’s 50 day moving average price is $71.51 and its 200 day moving average price is $73.18. BridgeBio Pharma has a 52 week low of $52.75 and a 52 week high of $93.42.

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.20). The company had revenue of $243.68 million during the quarter, compared to analysts’ expectations of $220.91 million. The firm’s revenue for the quarter was up 120.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.95) earnings per share. On average, sell-side analysts expect that BridgeBio Pharma will post -2.64 EPS for the current fiscal year.

Insider Activity at BridgeBio Pharma

In other news, CEO Neil Kumar sold 10,000 shares of the company’s stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $69.08, for a total value of $690,800.00. Following the completion of the transaction, the chief executive officer directly owned 495,686 shares in the company, valued at approximately $34,241,988.88. This represents a 1.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Maricel Apuli sold 2,000 shares of the stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $80.06, for a total value of $160,120.00. Following the completion of the transaction, the chief accounting officer directly owned 127,401 shares of the company’s stock, valued at $10,199,724.06. This represents a 1.55% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 56,980 shares of company stock valued at $4,578,119. 14.23% of the stock is owned by insiders.

Hedge Funds Weigh In On BridgeBio Pharma

Institutional investors have recently made changes to their positions in the stock. Hsbc Holdings PLC grew its position in BridgeBio Pharma by 139.4% in the 1st quarter. Hsbc Holdings PLC now owns 32,708 shares of the company’s stock worth $2,431,000 after purchasing an additional 19,043 shares during the last quarter. Assetmark Inc. lifted its stake in BridgeBio Pharma by 423.7% during the first quarter. Assetmark Inc. now owns 20,790 shares of the company’s stock valued at $1,544,000 after purchasing an additional 16,820 shares during the last quarter. EFG International AG acquired a new stake in BridgeBio Pharma during the second quarter valued at approximately $6,117,000. Corient Private Wealth LP bought a new stake in BridgeBio Pharma during the second quarter worth approximately $1,783,000. Finally, Squarepoint Ops LLC boosted its holdings in BridgeBio Pharma by 114.2% during the second quarter. Squarepoint Ops LLC now owns 1,191,732 shares of the company’s stock worth $88,760,000 after buying an additional 635,408 shares in the last quarter. 99.85% of the stock is owned by institutional investors.

About BridgeBio Pharma

(Get Free Report)

BridgeBio Pharma, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for genetically driven diseases. The company operates through a portfolio of subsidiary and affiliated biotechnology businesses, with research programs spanning rare diseases, oncology, cardiology and other conditions linked to underlying genetic or molecular causes.

BridgeBio’s portfolio includes therapies designed to address the root mechanisms of disease rather than primarily treating symptoms.